Novo Nordisk Slips on 2026 Sales Outlook Amid Ozempic/Wegovy Pressure
Novo Nordisk beat 2025 sales estimates but warned that 2026 sales will fall 5%–13% at constant exchange rates, reversing last year’s growth. The drop is driven by expected weaker U.S. sales amid competition from Lilly’s tirzepatide and pricing pressures under MFN reforms, even as international sales may rise with Wegovy expanding into more markets. The outlook sent the stock lower, with U.S.-listed shares sliding about 14% after the report.